MONTREAL, June 28 /PRNewswire/ - At last year’s annual meeting of the International Society for Pharmacoepidemiology, a series of presentations by leading epidemiologists raised grave concerns about the use of anti- inflammatory medications and the incidence of sudden-cardiac death.
The issues came to a head with the withdrawal from the marketplace of Vioxx, and led many regulatory agencies to review the safety not only of the COX2 category, but also of the processes used to approve pharmaceutical compounds for human therapy.
This year, ISPE will hold its 21st International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 21 to 24, 2005 in Nashville, Tennessee, USA.
According to 2005 Scientific Program Committee Chair Dr. Wayne A. Ray, FISPE, Director of Pharmaco-epidemiology, Vanderbilt University School of Medicine, researchers will again present bell-wether findings relating to human safety, risk management, drug policy and pharmaco-economics.
Some significant topics to be presented by epidemiologists from around the world will include:
- Cox-2 Selective Inhibitors and Acute Myocardial Infarction - Beta-Blockers, increased bone formation, decreased risk of hip and vertebral fractures - Antidepressant Use and Suicidality in Pediatric Patients - Isotretinoin, Pregnancies, Abortions, and Birth Defects ------------------------------------------------------- - Late Pregnancy Use of Selective Serotonin Reuptake Inhibitors and Risk for Persistent Pulmonary Hypertension in Newborns - Antiepileptic Drugs and Risk of Fractures - Trends in Prescribing of Antipsychotic Medications for US Children - Antihypertensive Therapy after ALLHAT: Are More Patients Starting with Diuretics? For details see: http://www.pharmacoepi.org/meetings/21stconf/index.aspx
Media representatives wishing to receive copies of abstracts, attend the conference and receive regular news updates should contact Charles Pitts as below.
ISPE
The International Society for Pharmacoepidemiology is a member-driven, not-for-profit forum of healthcare professionals dedicated to advancing the health of the public through open and global exchange of scientific information; a provider of education and an advocate in the fields of pharmacoepidemiology and therapeutic risk management for the development of policy among academia, government and industry, with members and national chapters in 40 countries. The ISPE official journal is - Pharmacoepidemiology and Drug Safety www.pharmacoepi.org
INTERNATIONAL SOCIETY FOR PHARMACOEPIDEMIOLOGY
CONTACT: Yola Moride, PhD Chair, Communications Committee InternationalSociety for Pharmacoepidemiology (ISPE), Montreal, (514) 343-6111 ext.1-3011, yola.moride@umontreal.ca ; Charles Pitts, Director Conference MediaRelations, Montreal, (514) 984-5614, cpitts@oroalliance.com ; Mark H.Epstein, ScD Executive Secretary International Society forPharmacoepidemiology (ISPE), Bethesda, USA, (301) 718-6537,mepstein@paimgmt.com